LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom ( UK ) 2.8 million injections of repackaged off-label bevacizumab in Europe each year 1 ISELIN, N.J.

ISELIN, N.J. , May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares

ISELIN, N.J. , May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.  (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common

LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom ( UK ) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J. , May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J. , April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the

ISELIN, N.J. , Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom ( UK ) for the first authorized use of an ophthalmic formulation of bevacizumab for the

On-demand video webcast now available here ISELIN, N.J. , Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom ( UK ) for the first authorized use of an ophthalmic

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025 LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom ( UK ) planned for Q2 CY2025 ISELIN, N.J. , Feb.

Dr. Jennifer Kissner , SVP Clinical Development , discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial Watch the “What This Means” segment here ISELIN, N.J. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that

ISELIN, N.J. , Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom ( UK ) for the first authorized use of an ophthalmic formulation of bevacizumab for the